General

Showing 1281–1296 of 2282 results

Article: Novel molecular genetic insights in paediatric B-cell precursor acute lymphoblastic leukaemia
€3.03 Add to cart
Article: Novel molecular insights and targeted therapies in T-cell acute lymphoblastic leukaemia
€3.03 Add to cart
Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant
€3.03 Add to cart
Article: Novel therapeutic targets in juvenile myelomonocytic leukaemia: Are noncoding RNAs valuable treatment options?
€3.03 Add to cart
Article: Novelties in the treatment of classical Hodgkin lymphoma
€3.03 Add to cart
Article: Novelties in the treatment of sickle cell disease
€3.03 Add to cart
Article: Numbers, Patterns and Timing: a systematic approach to a low platelet count in intensive care patients
€3.03 Add to cart
Article: O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy
€3.03 Add to cart
Article: O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial
€3.03 Add to cart
Article: O.1 Exome sequencing identifies mutation of the ribosome in T-ALL
€3.03 Add to cart
Article: O.1 Infusion of mesenchymal stem cells (MSC) as treatment for steroid refractory acute graft-versus-host study (aGVHD): a multicenter prospective phase II study of the BHS
€3.03 Add to cart
Article: O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival
€3.03 Add to cart
Article: O.1 Results from the Belgian mantle cell lymphoma registry
€3.03 Add to cart
Article: O.2 A single analysis for simultaneous measurement of all 4 DOACs
€3.03 Add to cart
Article: O.2 Analysis of Phenotype and Outcome in Essential Thrombocythemia with CALR and JAK2 mutations
€3.03 Add to cart
Article: O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers
€3.03 Add to cart

Article: Novel molecular genetic insights in paediatric B-cell precursor acute lymphoblastic leukaemia

Article: Novel molecular insights and targeted therapies in T-cell acute lymphoblastic leukaemia

Article: Novel therapeutic molecular targets in lung cancer: non-V600 mutant and mutant

Article: Novel therapeutic targets in juvenile myelomonocytic leukaemia: Are noncoding RNAs valuable treatment options?

Article: Novelties in the treatment of classical Hodgkin lymphoma

Article: Novelties in the treatment of sickle cell disease

Article: Numbers, Patterns and Timing: a systematic approach to a low platelet count in intensive care patients

Article: O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy

Article: O.1 ABVD (8 cycles) vs. BEACOPP (4 escalated cycles => 4 baseline) in stage III – IV low risk Hodgkin Lymphoma (IPS 0–2): final results of LYSA H34 trial

Article: O.1 Exome sequencing identifies mutation of the ribosome in T-ALL

Article: O.1 Infusion of mesenchymal stem cells (MSC) as treatment for steroid refractory acute graft-versus-host study (aGVHD): a multicenter prospective phase II study of the BHS

Article: O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

Article: O.1 Results from the Belgian mantle cell lymphoma registry

Article: O.2 A single analysis for simultaneous measurement of all 4 DOACs

Article: O.2 Analysis of Phenotype and Outcome in Essential Thrombocythemia with CALR and JAK2 mutations

Article: O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers